Hans‐Peter Guler

2.4k total citations · 1 hit paper
17 papers, 1.7k citations indexed

About

Hans‐Peter Guler is a scholar working on Endocrinology, Diabetes and Metabolism, Molecular Biology and Surgery. According to data from OpenAlex, Hans‐Peter Guler has authored 17 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Endocrinology, Diabetes and Metabolism, 12 papers in Molecular Biology and 4 papers in Surgery. Recurrent topics in Hans‐Peter Guler's work include Growth Hormone and Insulin-like Growth Factors (12 papers), Metabolism, Diabetes, and Cancer (10 papers) and Pancreatic function and diabetes (4 papers). Hans‐Peter Guler is often cited by papers focused on Growth Hormone and Insulin-like Growth Factors (12 papers), Metabolism, Diabetes, and Cancer (10 papers) and Pancreatic function and diabetes (4 papers). Hans‐Peter Guler collaborates with scholars based in Switzerland, United States and Netherlands. Hans‐Peter Guler's co-authors include Jürgen Zapf, E. R. Froesch, Christoph Schmid, E. R. Froesch, Raimund Hirschberg, Joel D. Kopple, Giuliano Brunori, Christian Bauer, Sherwyn Schwartz and Carl J. Scandella and has published in prestigious journals such as Nature, New England Journal of Medicine and Diabetes.

In The Last Decade

Hans‐Peter Guler

17 papers receiving 1.6k citations

Hit Papers

Insulin-like growth factors I and II in healthy man. 1989 2026 2001 2013 1989 100 200 300 400
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Insulin-like growth factors I and II in healthy man.
    1989 420 citations Hans‐Peter Guler, Jürgen Zapf et al. European Journal of Endocrinology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Hans‐Peter Guler Switzerland 11 1.2k 647 298 297 251 17 1.7k
C Lassarre France 22 1.6k 1.4× 786 1.2× 360 1.2× 130 0.4× 210 0.8× 33 2.0k
Brian L. Dake United States 20 754 0.6× 570 0.9× 165 0.6× 227 0.8× 138 0.5× 37 1.3k
G. Plewe Germany 14 1.1k 0.9× 350 0.5× 288 1.0× 223 0.8× 329 1.3× 19 1.6k
Blair E. Cox United States 18 451 0.4× 366 0.6× 182 0.6× 260 0.9× 361 1.4× 22 1.5k
Luisella Alberti Italy 26 625 0.5× 997 1.5× 275 0.9× 192 0.6× 284 1.1× 41 2.1k
Pierre-François Bougnères France 20 733 0.6× 559 0.9× 601 2.0× 432 1.5× 533 2.1× 53 1.8k
Lynn A. Burmeister United States 25 1.2k 1.0× 332 0.5× 193 0.6× 242 0.8× 301 1.2× 64 1.9k
J H Karam United States 17 812 0.7× 841 1.3× 618 2.1× 277 0.9× 705 2.8× 46 2.2k
Seong Yeon Kim South Korea 23 335 0.3× 614 0.9× 180 0.6× 188 0.6× 241 1.0× 51 1.4k
Anatoly Tiulpakov Russia 22 790 0.7× 637 1.0× 454 1.5× 102 0.3× 229 0.9× 131 1.5k

Countries citing papers authored by Hans‐Peter Guler

Since Specialization
Citations

This map shows the geographic impact of Hans‐Peter Guler's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hans‐Peter Guler with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hans‐Peter Guler more than expected).

Fields of papers citing papers by Hans‐Peter Guler

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hans‐Peter Guler. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hans‐Peter Guler. The network helps show where Hans‐Peter Guler may publish in the future.

Co-authorship network of co-authors of Hans‐Peter Guler

This figure shows the co-authorship network connecting the top 25 collaborators of Hans‐Peter Guler. A scholar is included among the top collaborators of Hans‐Peter Guler based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hans‐Peter Guler. Hans‐Peter Guler is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
1.
Bruijne, Joep de, Jianke Li, Xin Li, et al.. (2011). Pharmacokinetics and Antiviral Activity of Phx1766, a Novel HCV Protease Inhibitor, Using An Accelerated Phase I Study Design. Antiviral Therapy. 17(2). 365–375. 7 indexed citations
2.
3.
Vliet, André van, Julie M. Cherrington, David A. Campbell, et al.. (2007). Pharmacokinetic and Pharmacodynamic Assessments of the Dipeptidyl Peptidase-4 Inhibitor PHX1149: Double-Blind, Placebo-Controlled, Single- and Multiple-Dose Studies in Healthy Subjects. Clinical Therapeutics. 29(8). 1692–1705. 26 indexed citations
4.
Ettinger, Mark P., Thomas Littlejohn, Sherwyn Schwartz, et al.. (2003). Recombinant variant of ciliary neurotrophic factor for weight loss in obese adults: a randomized, dose-ranging study.. PubMed. 289(14). 1826–32. 151 indexed citations
5.
Schalch, Paul, et al.. (1994). Adverse Effects of Recombinant Human Insulin-like Growth Factor I in Obese Insulin-Resistant Type II Diabetic Patients. Diabetes. 43(3). 369–374. 90 indexed citations
6.
Hirschberg, Raimund, Giuliano Brunori, Joel D. Kopple, & Hans‐Peter Guler. (1993). Effects of insulin-like growth factor I on renal function in normal men. Kidney International. 43(2). 387–397. 100 indexed citations
7.
Morgan, John, David M. Capuzzi, William R. Good, et al.. (1993). Hypoglycemic and Insulin Response to a Continuous Intravenous Infusion of CGP‐35126 Recombinant Human Insulin‐Like Growth Factor‐I (rhIGF‐I) in Healthy Males. The Journal of Clinical Pharmacology. 33(4). 366–372. 2 indexed citations
8.
Guler, Hans‐Peter, et al.. (1991). Recombinant Human Insulin-Like Growth Factor I: Effects in Normal Subjects and Implications for Use in Patients. Advances in experimental medicine and biology. 293. 97–104. 6 indexed citations
9.
Froesch, E. R., Hans‐Peter Guler, Christoph Schmid, Katharina Binz, & Jürgen Zapf. (1990). Therapeutic potential of insulinlike growth factor i. Trends in Endocrinology and Metabolism. 1(5). 254–260. 30 indexed citations
10.
Guler, Hans‐Peter, Jürgen Zapf, Christoph Schmid, & E. R. Froesch. (1989). Insulin-like growth factors I and II in healthy man.. European Journal of Endocrinology. 121(6). 753–758. 420 indexed citations breakdown →
11.
Guler, Hans‐Peter, et al.. (1989). Insulin-like growth factor I increases glomerular filtration rate and renal plasma flow in man. European Journal of Endocrinology. 121(1). 101–106. 121 indexed citations
12.
Guler, Hans‐Peter, et al.. (1989). Small stature and insulin-like growth factors: prolonged treatment of mini-poodles with recombinant human insulin-like growth factor I. European Journal of Endocrinology. 121(3). 456–464. 9 indexed citations
13.
Schmid, Christoph, Hans‐Peter Guler, David Rowe, & E. R. Froesch. (1989). Insulin-Like Growth Factor I Regulates Type I Procollagen Messenger Ribonucleic Acid Steady State Levels in Bone of Rats*. Endocrinology. 125(3). 1575–1579. 78 indexed citations
14.
Zenobi, P D, Hans‐Peter Guler, Jürgen Zapf, & E. R. Froesch. (1988). Insulin-like growth factors in the Göttinger miniature-pig. European Journal of Endocrinology. 117(3). 343–352. 16 indexed citations
15.
Guler, Hans‐Peter, Jürgen Zapf, & E. R. Froesch. (1987). Short-Term Metabolic Effects of Recombinant Human Insulin-like Growth Factor I in Healthy Adults. New England Journal of Medicine. 317(3). 137–140. 450 indexed citations
16.
Guler, Hans‐Peter, et al.. (1986). Growth restoration of insulin-deficient diabetic rats by recombinant human insulin-like growth factor I. Nature. 323(6084). 169–171. 142 indexed citations
17.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by C Lassarre Breakdown of academic impact, for papers by Brian L. Dake Breakdown of academic impact, for papers by G. Plewe Breakdown of academic impact, for papers by Blair E. Cox Breakdown of academic impact, for papers by Luisella Alberti Breakdown of academic impact, for papers by Pierre-François Bougnères Breakdown of academic impact, for papers by Lynn A. Burmeister Breakdown of academic impact, for papers by J H Karam Breakdown of academic impact, for papers by Seong Yeon Kim Breakdown of academic impact, for papers by Anatoly Tiulpakov
Rankless by CCL
2026